Mario Cazzola
Mario Cazzola is an expert in Pulmonology at University of Rome Tor Vergata (Italy). As of October 2026, ScienceLeadR ranks Mario Cazzola in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Mario Cazzola has authored 935 publications, the most recent in 2026, and is an investigator in 6 clinical trials. SLR score: 3,039 (community average: 125). How the SLR is computed.
LeadR Profile
Pulmonology
Subspecialties: Pharmacy - Immunology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1987 - 2026
Number : 935
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Serum Angiopoietin-1 and Angiopoietin-2 as Biomarkers of Pulmonary Hemodynamic Burden in COPD-Associated Pulmonary Hypertension: A Cross-Sectional Study. PMID 42644880 — hypertension, cross-sectional studies, hypertension, pulmonary, serum, biomarkers, pulmonary disease, chronic obstructive, vascular remodeling, echocardiography, angiopoietin-1, angiopoietins, hemodynamics, angiopoietin-2 | Adv Respir Med | 2026 | 0 |
| Expert consensus on the Management of Mild and Moderate Asthma. PMID 42562236 — patient compliance, therapeutics, asthma | Respir Med | 2026 | 0 |
| From Signal to Certainty: Why COPD Needs More Than One Trial. PMID 42536190 — lung, respiration, biomarkers, pulmonary disease, chronic obstructive, therapeutics, lung diseases | Lung | 2026 | 0 |
| Hypoglycaemic Agents and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease. PMID 42521255 — respiratory system, pulmonary disease, chronic obstructive, lung diseases, lung diseases, obstructive, diabetes mellitus, type 2 | Respirology | 2026 | 0 |
| Age-Specific Considerations in Bronchiectasis Management: Focus on Older Adults with Emphasis on Anti-inflammatory Treatment. PMID 42479305 — drug therapy, therapeutics, bronchiectasis | Drugs Aging | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
LeadR Networks
Main global connection map